These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 27107614

  • 1. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, Wang J, Zhao B, Li N, Jiang M.
    Virus Res; 2016 Jul 15; 220():97-103. PubMed ID: 27107614
    [Abstract] [Full Text] [Related]

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE, Wui SR, Park SA, Lee NG, Kim KS, Cho YJ, Kim HJ, Kim HJ.
    Vaccine; 2012 Jun 13; 30(28):4127-34. PubMed ID: 22561312
    [Abstract] [Full Text] [Related]

  • 4. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A, Gómez-Lim MA, Weiss-Steider B, Hernández-Montes J, Huerta-Yepez S, Rangel-Santiago JF, Santiago-Osorio E, Mora García Mde L.
    Arch Virol; 2014 Feb 13; 159(2):291-305. PubMed ID: 23990055
    [Abstract] [Full Text] [Related]

  • 5. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X, Zhang T, Liu H, Hao Y, Liao G, Xu X.
    Hum Vaccin Immunother; 2018 Feb 13; 14(8):2025-2033. PubMed ID: 29683766
    [Abstract] [Full Text] [Related]

  • 6. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N.
    Protein Expr Purif; 2015 Dec 13; 116():7-11. PubMed ID: 26304732
    [Abstract] [Full Text] [Related]

  • 7. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 8. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [Abstract] [Full Text] [Related]

  • 9. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M, Wang D, Li Z, Song S, Kong X, Mo X, Yang Y, He M, Li Z, Huang B, Lin Z, Pan H, Zheng Q, Yu H, Gu Y, Zhang J, Li S, Xia N.
    Emerg Microbes Infect; 2018 Sep 26; 7(1):160. PubMed ID: 30254257
    [Abstract] [Full Text] [Related]

  • 10. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.
    López-Toledo G, Schädlich L, Alonso-Castro ÁJ, Monroy-García A, García-Rocha R, Guido MC, Gissmann L, García-Carrancá A.
    Viral Immunol; 2016 Jun 26; 29(5):276-87. PubMed ID: 27058179
    [Abstract] [Full Text] [Related]

  • 11. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
    Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA.
    Virol J; 2009 Jan 06; 6():2. PubMed ID: 19126233
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C, Dey B, Wahiduzzaman M, Singh N.
    Vaccine; 2012 Aug 03; 30(36):5417-24. PubMed ID: 22717329
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, Schiller JT, Graham BS.
    PLoS One; 2015 Aug 03; 10(3):e0120797. PubMed ID: 25785935
    [Abstract] [Full Text] [Related]

  • 14. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.
    Clin Vaccine Immunol; 2007 Oct 03; 14(10):1285-95. PubMed ID: 17687110
    [Abstract] [Full Text] [Related]

  • 15. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B.
    Vaccine; 2015 Jun 26; 33(29):3346-53. PubMed ID: 26003490
    [Abstract] [Full Text] [Related]

  • 16. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
    Zhang T, Chen X, Liao G, Hu M, Xu J, Xu X.
    J Med Virol; 2020 Dec 26; 92(12):3750-3758. PubMed ID: 31994744
    [Abstract] [Full Text] [Related]

  • 17. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
    Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA.
    Vaccine; 2011 Oct 06; 29(43):7326-34. PubMed ID: 21803095
    [Abstract] [Full Text] [Related]

  • 18. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO, Seo JW, Kwon O, Park SM, Kim CH, Kim IH.
    Enzyme Microb Technol; 2012 Mar 10; 50(3):173-80. PubMed ID: 22305172
    [Abstract] [Full Text] [Related]

  • 19. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E, Peabody J, Peabody DS, Chackerian B.
    PLoS One; 2011 Mar 10; 6(8):e23310. PubMed ID: 21858066
    [Abstract] [Full Text] [Related]

  • 20. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D, Zosso N, Nardelli-Haefliger D.
    Vaccine; 2009 Apr 14; 27(17):2326-34. PubMed ID: 19428847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.